SEC Form 4Coverage since Jul 1, 2026
$EBS insider trading
Over the last 12 months, Emergent BioSolutions insiders reported no purchases and 1 sale totaling $25K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $25K 1 event
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $EBS · 12Mvia TradingView
Top insiders · 12m
Williams Paul AnthonySVP, Products Business1× · $25K
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Williams Paul AnthonySVP, Products Business · O | ▼ Sale | 3,000 | $8.4 | $25K | -1.9% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $EBS feed.